Foster S A, Foley K A, Meadows E S, Johnston J A, Wang S, Pohl G M, Long S R
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Osteoporos Int. 2008 Mar;19(3):373-7. doi: 10.1007/s00198-007-0455-4. Epub 2007 Aug 21.
The demographic and clinical characteristics of patients initiating teriparatide were compared with those of patients initiating bisphosphonates for the treatment of osteoporosis. In these samples of commercially insured, Medicare, and Medicaid patients, patients initiating teriparatide were older, in poorer health, and appeared to have more severe osteoporosis than patients initiating bisphosphonates.
The demographic and clinical characteristics of patients initiating teriparatide are compared with those of patients initiating bisphosphonates.
Beneficiaries (45 years and older) with at least one claim for teriparatide or a bisphosphonate from 2003 to 2005 and continuous enrollment in the previous 12 months and subsequent 6 months were identified from commercial, Medicare, and Medicaid administrative claims databases. Patients initiating teriparatide (commercial/Medicare (N = 2,218); Medicaid (N = 824)) were compared to patients initiating bisphosphonates (commercial/Medicare (N = 97,570); Medicaid (N = 77,526)) in terms of age, provider specialty, comorbidities, prior use of osteoporosis medications, fractures, BMD screening, health status, and resource utilization.
Teriparatide patients were older and in poorer health than bisphosphonate patients. Approximately 38% of teriparatide patients in both groups had fractured in the pre-period compared to 16% of commercial/Medicare and 15% of Medicaid bisphosphonate patients. Teriparatide patients were more likely to have used osteoporosis medications in the pre-period (79.9% versus 32.1% (commercial/Medicare); 82.2% versus 19.6% (Medicaid)).
In these samples of patients, those initiating teriparatide differed from those initiating bisphosphonates. Teriparatide patients were older, in poorer health, and appeared to have more severe osteoporosis than bisphosphonate patients. Comparisons of treatment outcomes should take these differences in patient characteristics into consideration.
将开始使用特立帕肽的患者的人口统计学和临床特征与开始使用双膦酸盐治疗骨质疏松症的患者的特征进行了比较。在这些商业保险、医疗保险和医疗补助患者样本中，开始使用特立帕肽的患者年龄更大，健康状况更差，并且与开始使用双膦酸盐的患者相比，似乎患有更严重的骨质疏松症。
将开始使用特立帕肽的患者的人口统计学和临床特征与开始使用双膦酸盐的患者的特征进行比较。
从商业、医疗保险和医疗补助行政索赔数据库中识别出2003年至2005年期间至少有一次特立帕肽或双膦酸盐索赔记录，且在之前12个月和随后6个月持续参保的45岁及以上受益人。在年龄、医疗服务提供者专业、合并症、既往骨质疏松症药物使用情况、骨折情况、骨密度筛查、健康状况和资源利用方面，将开始使用特立帕肽的患者（商业保险/医疗保险（N = 2218）；医疗补助（N = 824））与开始使用双膦酸盐的患者（商业保险/医疗保险（N = 97570）；医疗补助（N = 77526））进行比较。
特立帕肽组患者比双膦酸盐组患者年龄更大，健康状况更差。两组中约38%的特立帕肽患者在前期发生过骨折，而商业保险/医疗保险双膦酸盐组患者为16%，医疗补助双膦酸盐组患者为15%。特立帕肽组患者在前期更有可能使用过骨质疏松症药物（商业保险/医疗保险组为79.9%对32.1%；医疗补助组为82.2%对19.6%）。
在这些患者样本中，开始使用特立帕肽的患者与开始使用双膦酸盐的患者不同。特立帕肽组患者年龄更大，健康状况更差，并且与双膦酸盐组患者相比，似乎患有更严重的骨质疏松症。治疗结果的比较应考虑患者特征的这些差异。
